Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRCP | P42785 | 8/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.51 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | GID4 | Q8IVV7 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28750379 | 0.77 | ADRA1A (0.43) | GID4ALDH1A1 | |
| SCHEMBL6412287 | 0.75 | SLC6A3 (0.39) | — | |
| SCHEMBL7481839 | 0.73 | FLT3 (0.37) | MAPT | |
| SCHEMBL30833186 | 0.72 | HTR7 (0.63) | ALDH1A1 | |
| SCHEMBL1597975 | 0.72 | KDM1A (0.69) | PRCPGAARECQLGID4TSHR | |
| SCHEMBL7697942 | 0.72 | PRCP (0.54) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL7697938 | 0.72 | PRCP (0.54) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL2676256 | 0.71 | PRCP (0.59) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL28547431 | 0.70 | PRCP (0.53) | PRCPGAARECQLGID4MAPT | |
| SCHEMBL12046710 | 0.70 | PRCP (1.00) | PRCPGAARECQLGID4SLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116041319-B | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-08-25 | — | — | CN | claimed |
| CN-116041319-A | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-05-02 | — | — | CN | claimed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | claimed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | claimed |
| CN-116041319-B | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116041319-B | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116041319-B | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-08-25 | — | — | CN | disclosed |
| CN-116041319-A | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041319-A | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| CN-116041319-A | Preparation method of indolyl tetrahydroisoquinoline derivative | 江苏中利集团股份有限公司 | 2023-05-02 | — | — | CN | disclosed |
| WO-2004082686-A2 | USE OF COMPOUNDS WITH COMBINED 5-HT1A AND SSRI ACTIVITIES TO TREAT SEXUAL DYSFUNCTION | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | WO | disclosed |
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | DYNOGEN PHARMACEUTICALS, INC. (US) | 2004-09-30 | — | — | US | disclosed |
| CN-1348450-A | Tetrahydroisoquinolinyl-indole derivatives for the treatment of depression | AMERICAN HOME PROD (US) | 2002-05-08 | — | — | CN | disclosed |
| US-6245780-B1 | PSYCHOLOGICAL DISORDERS | AMERICAN HOME PRODUCTS CORP | 2001-06-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040192730-A1 | Methods of using compounds with combined 5-HT1A and SSRI activities as-needed to treat sexual dysfunction | HTR5A, HTR1A, HTR3A | PRCP 817/4885GAA 1474/4885RECQL 3260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.